An experimental antibody has outperformed an established immunotherapy in a head-to-head trial for one of the harder-to-treat forms of lung cancer. In patients with advanced squamous non-small-cell lung cancer, the drug ivonescimab combined with chemotherapy reduced the risk of death compared with a standard immunotherapy regimen, according to results presented at a major oncology meeting.
The HARMONi-6 trial
The comparison came from HARMONi-6, a phase 3 study that pitted ivonescimab plus chemotherapy against tislelizumab plus chemotherapy in people with advanced squamous non-small-cell lung cancer. Tislelizumab is an approved PD-1 checkpoint immunotherapy, making it a meaningful benchmark rather than a placebo, so the trial was a direct test of one active regimen against another already in use.
The results were reported at the 2026 meeting of the American Society of Clinical Oncology. According to ecancer, the ivonescimab combination improved overall survival relative to the standard immunotherapy regimen, adding to earlier evidence that it slowed the cancer’s progression. Head-to-head comparisons against an active drug are held to a higher bar than tests against placebo, which is part of why the finding drew notice.
A two-target antibody
Ivonescimab is a bispecific antibody, meaning it is engineered to latch onto two targets at once. It blocks PD-1, the same immune brake that existing checkpoint drugs release, while also binding VEGF, a signal that tumors use to build the blood vessels they need to grow. The dual action is intended to unleash an immune attack and starve the tumor’s blood supply at the same time, combining into a single molecule what has often required two separate drugs.
The antibody is already approved in China but remains investigational in the United States, where it is still moving through phase 3 development, as summarized by the American Society of Clinical Oncology. That status is why the antibody is described as experimental in the U.S. context even as evidence for it accumulates abroad.
Squamous lung cancer’s stubbornness
Squamous non-small-cell lung cancer has historically offered fewer targeted treatment options than other lung-cancer subtypes, which is part of why an improvement in survival draws notice. Patients with advanced disease have long faced limited choices once first-line treatment fails, so a regimen that extends life in a direct comparison against a current standard addresses a real gap in care.
The trial focused specifically on this subtype, and its findings should be read as applying to squamous disease rather than to lung cancer as a whole. That precision matters, because treatments that help one form of lung cancer do not always translate to another.
Lung cancer remains the leading cause of cancer death worldwide, and the squamous form accounts for a significant share of non-small-cell cases. Many patients are diagnosed at an advanced stage, when a cure is rarely possible and the goal of treatment shifts to extending life and controlling symptoms. Against that backdrop, even an incremental gain in survival can be meaningful for a large number of people.
The survival and progression numbers
In the trial, ivonescimab plus chemotherapy reduced the risk of death by 34 percent compared with the tislelizumab regimen. Earlier data from the same study had shown the antibody kept the cancer from progressing for longer, with progression-free survival of roughly 11 months versus about 9 months for the comparator, as reported by Managed Healthcare Executive.
The survival benefit is what elevated the result, because extending overall survival, not just delaying progression, is the outcome oncologists weigh most heavily when judging a new therapy. Progression-free survival measures how long a cancer is held in check, but living longer is the endpoint that ultimately defines a treatment’s value.
What remains to be confirmed
The findings do not yet translate into a treatment available in the United States, where the drug is not approved and where longer follow-up will be needed. Because ivonescimab targets VEGF, clinicians are also watching for bleeding and other side effects associated with that mechanism, since drugs that interfere with blood-vessel signaling can carry distinctive risks.
A separate late-stage trial is testing the antibody against pembrolizumab, another widely used checkpoint immunotherapy, which will provide a further comparison before the drug’s place in treatment is settled. For now, the result stands as a head-to-head trial in which an experimental antibody outperformed a standard immunotherapy, a promising but still-developing step for a cancer that has proven difficult to treat.
The trial also reflects a broader trend toward bispecific antibodies, which attempt to fold the effects of multiple drugs into a single molecule. Whether that design proves durably better than combining existing agents will depend on longer follow-up and on how the treatment performs across different patient populations and against different comparators. The HARMONi-6 result is a strong data point, but the field will want to see it hold up before treatment guidelines are rewritten.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
